Literature DB >> 11757627

Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers.

M E Broeders1, J Molema, N A Vermue, H T Folgering.   

Abstract

Aerosol delivery depends on device design and inhalation technique. In vitro device evaluations have shown that the emitted dose and fine particle mass of dry powder inhalers (DPIs) increase at high peak inspiratory flow rates (PIFR). Since the PIFR is mostly achieved after the release of the powder, slope of the pressure profile is also described as an important determinant. The aim of the present study was to assess whether the PIFR while using Diskus it and Turbuhaler it inhalers could be used to predict the slope of the inhalation pressure profile. In a group of 10 stable asthma patients and three groups (mild, moderate and severe) of 16 chronic obstructive pulmonary disease (COPD) patients, lung function was measured, and for each device, 18 inhalation profiles were recorded with the inhalation profile recorder during six sessions over 10 weeks. The values for the pressure slope and PIFR of both Diskus and Turbuhaler, were significantly correlated. The r-values were 0.865 and 0.882, respectively (p<0.01). Percentage explained variance was 74.8% for Diskus and 77.8% for Turbuhaler. Significant correlations were found between peak inspiratory flow rates and slopes. It has been shown for two different dry powder inhalers that peak inspiratory flow rate and slope correlate well in a wide range of patient groups.

Entities:  

Mesh:

Year:  2001        PMID: 11757627     DOI: 10.1183/09031936.01.00240301

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

1.  Personalization of Device Therapy - Prime Time for Peak Inspiratory Flow Rate.

Authors:  Chee H Loh; Jill A Ohar
Journal:  Chronic Obstr Pulm Dis       Date:  2017-07-14

Review 2.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.

Authors:  Sohini Ghosh; Jill A Ohar; M Bradley Drummond
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-09-21       Impact factor: 2.849

3.  Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.

Authors:  Wahida Azouz; Philip Chetcuti; Harold Hosker; Dinesh Saralaya; Henry Chrystyn
Journal:  BMC Pulm Med       Date:  2015-05-01       Impact factor: 3.317

4.  Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD.

Authors:  Anthony D'Urzo
Journal:  Ther Clin Risk Manag       Date:  2013-08-19       Impact factor: 2.423

5.  Spiromax, a New Dry Powder Inhaler: Dose Consistency under Simulated Real-World Conditions.

Authors:  Giorgio Walter Canonica; Jan Arp; Johan René Keegstra; Henry Chrystyn
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-09-09       Impact factor: 2.849

6.  Evaluation of proficiency in using different inhaler devices among intern doctors.

Authors:  Ravish M Kshatriya; Nimit V Khara; Rajiv P Paliwal; Satish N Patel
Journal:  J Family Med Prim Care       Date:  2016 Apr-Jun

7.  Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Authors:  David Prime; Wilfried de Backer; Melanie Hamilton; Anthony Cahn; Andrew Preece; Dennis Kelleher; Amanda Baines; Alison Moore; Noushin Brealey; Jackie Moynihan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-09-15       Impact factor: 2.849

8.  Peak Inspiratory Flow Rate: An Emerging Biomarker in Chronic Obstructive Pulmonary Disease.

Authors:  Donald A Mahler
Journal:  Am J Respir Crit Care Med       Date:  2019-06-15       Impact factor: 21.405

9.  Inspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.

Authors:  Mark R Elkins; Philip Robinson; Sandra D Anderson; Clare P Perry; Evangelia Daviskas; Brett Charlton
Journal:  Open Respir Med J       Date:  2014-01-24

10.  Inspiratory Flows and Volumes in Subjects with Non-CF Bronchiectasis Using a New Dry Powder Inhaler Device.

Authors:  Mark R Elkins; Sandra D Anderson; Clare P Perry; Evangelia Daviskas; Brett Charlton
Journal:  Open Respir Med J       Date:  2014-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.